March 31, 2005
11a.m.-3p.m.
Members Present:
Kendra Grande, Richard Johnson, Mike Carpenter, Lenny Kosirog, Bill Harrison,
Dean Winsch, Scott Johnston, Antoinette Brown, Deb Devereaux, Steve Brown, Bill
Keenan
Members Excused:
Becky Drnas, George Zaharas, Roxanne Homar
Guests: Brittani
Parks (UW pharmacy student), Chris Meyer (UW Pharmacy student), Raquel Romero
(UW pharmacy Student)
I.
Minutes
of the January 27, 2005 meeting were approved as corrected.
II.
Department
of Health
Prior
authorization-the Board agreed that for the PPIs, a trial of one preferred
agent would be the criteria. Statistically, the most requests by class are as
follows: PPIs, CoxIIs, CaChannel Blockers, Narcotics. PPI costs have declined
from $110/claim to $91/claim. ACEI costs have declined from $33/claim to
$25/claim. There is a $10.16
administrative fee per PA claim.
PDL-schedule
to be announced after Aimee’s return
A
116 page cost report was recently completed for the Governor’s office. The
pharmacy program costs are presently contained due to the effects of PA and PDL
over the past 18 months.
Medicare
Drug Benefit-barbiturates, benzodiazepines, and OTCs will not be covered by the
program. The analysis of the duals is appended to the minutes.
III.
New
Board Members
Dr.
Jane Robinett and Dr. Kurt Hopfensperger will be joining the WYDUR Board as
physician members. Their first meeting will be the July meeting in
IV.
Presentations
Brittani
Parks presented “Dose Conversion to Felodipine from other Dihydropyridine
Calcium Channel Blockers” which is appended to the minutes. There are no
definitive conversion studies-all the information points to dependence on
prescriber clinical judgment and monitoring.
Raquel
Romero and Chris Meyer presented prescriber and patient information on
amiodarone. Presently the FDA requires that a package insert be given to all
patients on the drug. The report is appended to the minutes.
V.
Other
1.
The
Board requested written guidance on Board liability for PA appeal decisions and
general Board liability.
2.
Newsletter
suggestions: acquire CME accreditation and make available on-line, recommended
web-sites for patient information.
3.
Kendra
will coordinate conversion article for web-site and newsletter (conversions for
other than PDL preferred agents in all classes)
4.
A
letter will be sent to providers about the black box warning for Eladyl and
Protopic use.
5.
What
is usage of gabitril? What is it being used for at what cost?
6.
Lunesta
is new sedative/hypnotic approved for long term use.
7.
www.
Mtmedicaid.org is website for Montana PDL list.
VI.
Alert
changes
#488
suppress-thiazides and diabetes
#00041
suppress
#00310
delete –benzodiazepines and COPD
Respectfully
Submitted,
Debra
S. Devereaux MBA, FASHP
WYDUR
Manager